Latest news and press releases about AIM ImmunoTech Inc. (AIM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.
Price
| Price | $0.21 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.40 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 952.76% |
| Return on Invested Capital | -94.78% |
| Return on Assets | -112.09% |
| Gross Margin | -125.26% |
| Operating Margin | -11637.89% |
| Net Margin | -15021.05% |
Related companies: CANF · ENSC · KALA · KTTA · OGEN · QNRX · SNGX
Explore sector: Healthcare · Biotechnology
More sections of AIM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks